Financiado en parte por Quest Diagnostics
Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial
Wetmore JB, Kimber C, Mahnken JD, Stubbs JR
The British journal of nutrition · 25 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Quest Diagnostics
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NIDDK NIH HHS
- Gobierno
- NCATS NIH HHS
- Subvenciones
- National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK085378); National Center for Advancing Translational Sciences (UL1TR000001)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2016-12-28 · Br J Nutr · vol. 116 · número 12 · págs. 2074–2081
- Editorial
- Cambridge University Press
- Citado
- 35 citas · más que el 92% de estudios similares · 3.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Pancreatitis Pathology and Treatment
- Palabras clave
- Ergocalciferol, Cholecalciferol, Vitamin D and neurology, Medicine, Internal medicine, vitamin D deficiency, Endocrinology, Kidney disease, Gastroenterology, Parathyroid hormone, Population, Calcium
- MeSH
- humans, vitamin d deficiency, cholecalciferol, calcifediol, calcitriol, ergocalciferols, 25-hydroxyvitamin d 2, parathyroid hormone, cohort studies, follow-up studies, double-blind method, reproducibility of results, dietary supplements, adult, aged, middle aged, academic medical centers, outpatient clinics, hospital, kansas, female, male, renal insufficiency, chronic
4 autores
- James B. Wetmore🇺🇸Hennepin County Medical Center
- Cassandra Kimber🇺🇸University of Kansas Medical Center
- Jonathan D. Mahnken🇺🇸University of Kansas Medical Center
- Jason R. Stubbs🇺🇸 · autor de correspondenciaUniversity of Kansas Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Patients with chronic kidney disease (CKD) demonstrate complex mineral metabolism derangements and a high prevalence of vitamin D deficiency. However, the optimal method of 25-hydroxyvitamin D (25(OH)D) repletion is unknown, and trials analysing the comparative efficacy of cholecalciferol and ergocalciferol in this population are lacking. We conducted a randomised clinical trial of cholecalciferol 1250μg (50 000 IU) weekly v. ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks in forty-four non-dialysis-dependent patients with stage 3-5 CKD. The primary outcome was change in total 25(OH)D from baseline to week 12 (immediately after therapy). Secondary analyses included the change in 1,25-dihydroxyvitamin D (1,25(OH)2D), parathyroid hormone (PTH), D2 and D3 sub-fractions of 25(OH)D and 1,25(OH)2D and total 25(OH)D from baseline to week 18 (6 weeks after therapy). Cholecalciferol therapy yielded a greater change in total 25(OH)D (45·0 (sd 16·5) ng/ml) v. ergocalciferol (30·7 (sd 15·3) ng/ml) from baseline to week 12 (P<0·01); this observation partially resulted from a substantial reduction in the 25(OH)D3 sub-fraction with ergocalciferol. However, following cessation of therapy, no statistical difference was observed for total 25(OH)D change from baseline to week 18 between cholecalciferol and ergocalciferol groups (22·4 (sd 12·7) v. 17·6 (sd 8·9) ng/ml, respectively; P=0·17). We observed no significant difference between these therapies with regard to changes in serum PTH or 1,25(OH)2D. Therapy with cholecalciferol, compared with ergocalciferol, is more effective at raising serum 25(OH)D in non-dialysis-dependent CKD patients while active therapy is ongoing. However, levels of 25(OH)D declined substantially in both arms following cessation of therapy, suggesting the need for maintenance therapy to sustain levels.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.